Type 2 diabetes and life insurance

Where most applicants land

Type 2 accounts for the large majority of diagnosed diabetes in Canada, and it is one of the most frequently underwritten conditions there is. Insurers have extensive experience with it and a settled approach to assessing it.

Outcomes cover a wider spread than for Type 1. Standard rates are genuinely achievable for some applicants, particularly where diagnosis came later in life, control has been steady, treatment is straightforward and nothing else complicates the picture. Ratings are common. Declines are the minority and usually reflect documented complications, recent instability, or a combination of factors rather than the diabetes alone.

Age at diagnosis works differently here

For Type 2, being diagnosed later is generally read more favourably, which is the reverse of what people often assume.

The logic is exposure. Someone diagnosed at 58 who applies at 61 has had the condition for three years and will have it for however many years remain. Someone diagnosed at 34 who applies at 61 has had it for twenty-seven years, and the risk of complications accumulates over that time.

So a recent diagnosis in later life is often assessed relatively gently, while a long-standing diagnosis from early adulthood attracts closer attention even where current readings are similar.

Treatment is read as a trajectory

This is the factor most specific to Type 2, and the one that surprises applicants.

Underwriters do not just note what you take. They read the sequence. Type 2 is typically managed in steps, beginning with lifestyle measures, then oral medication, then additional or injectable agents, and for some people eventually insulin.

Where someone sits on that path, and how quickly they moved along it, tells an underwriter something about how the condition is behaving. A person on the same single medication for eight years with steady readings presents very differently from someone who has had three additions to their regimen in two years, even if both have similar current numbers.

Insulin. Moving onto insulin generally affects the assessment. It is not treated identically to Type 1, since the underlying condition is different, and it does signal that other approaches have not been sufficient. Many insurers still make offers to applicants with Type 2 on insulin.

Newer injectable medications. Treatment for Type 2 has changed considerably in recent years, and insurer guidelines have not all moved at the same pace. This is one of the areas where the variation between companies is currently widest, which is a practical argument for not relying on a single application.

What rarely arrives alone

Type 2 usually comes with company, and underwriters assess the combination rather than the diabetes in isolation.

Blood pressure, cholesterol and weight are all commonly elevated alongside it, and each is a factor on its own. Where several appear together, the assessment reflects the cluster rather than adding the items separately. Those are covered in high blood pressure, high cholesterol and height, weight and life insurance.

Nicotine use alongside Type 2 is a significant combination and affects the outcome more than either factor would alone.

The practical consequence is that a file where the diabetes is the only thing on it is assessed very differently from one where it sits within a broader picture.

Complications

As with any diabetes, documented complications carry the most weight. Kidney function and protein in the urine, eye examinations, nerve and foot findings, and any cardiovascular history all feed in.

For Type 2 specifically, cardiovascular findings are the ones most likely to change an assessment materially, because the pathways overlap. A history of coronary artery disease alongside Type 2 is a different file from Type 2 alone, and it is assessed on the terms described in coronary artery disease.

Remission

Some people with Type 2 reach a point where blood glucose sits in the normal range without glucose-lowering medication. Clinically this is described as remission rather than cure.

Underwriters treat this cautiously but not dismissively. What tends to matter is how long the situation has held, whether it is documented in your records, and whether the underlying factors have changed durably. A short period without medication is usually not enough for an insurer to reassess. A sustained and documented picture over years can be.

If this applies to you, make sure your records reflect it rather than relying on describing it on the application. What is in the file is what gets assessed.

Applying

Apply fully underwritten first. For Type 2 in particular, the range of outcomes is wide enough that assuming the worst costs real money.

Bring the details: diagnosis date, current medications and doses, how long you have been on them, recent bloodwork, and when you last had eye and kidney screening.

If a rating comes back, ask whether it can be reviewed later. Ratings on Type 2 are frequently reconsidered where the record shows sustained stability, and insurers do remove them. See ratings and substandard offers.

A necessary boundary

This page describes how insurers read a file. It is not guidance about managing Type 2 diabetes, and nothing here is a target or a recommendation. Those decisions sit with your doctor, and they matter for reasons entirely separate from any insurance application.